findmyKOL
Clinical trialNCT03095781CompletedPhase 1Interventional

Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer

SponsorEmory UniversityEnrollment47Colorectal AdenocarcinomaMetastatic Pancreatic AdenocarcinomaRecurrent Colorectal CarcinomaRecurrent Pancreatic CarcinomaStage III Colorectal CancerStage III Pancreatic Cancer+9 more conditions
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This phase Ib trial studies the side effects and best dose of Hsp90 inhibitor XL888 when given together with pembrolizumab in treating patients with advanced gastrointestinal cancer that has spread to other places in the body. XL888 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as pembrolizumab, may block tumor growth in different ways by targeting certain cells. Giving XL888 with pembrolizumab may work better in treating patients with gastrointestinal cancer.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Emory Saint Joseph'S Hospital

    Atlanta, Georgia, United States

  • Emory University Hospital Midtown

    Atlanta, Georgia, United States

  • Emory University/winship Cancer Institute

    Atlanta, Georgia, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Pembrolizumab →XL-888
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
7 Jul 2017
Primary completion
10 Jun 2021
Completion
10 Jun 2021
Last update posted
22 May 2026
Registered enrollment
47
Registry id
NCT03095781
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.